Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Janssen Plans Tiered Pricing For Sirturo In India; Will Work With Government Agencies For Right Use

This article was originally published in The Pink Sheet Daily

Executive Summary

The TB treatment will be brought to India with a tiered-pricing mechanism, but Janssen says it will work with partners to ensure appropriate use in a country with the highest population of MDR-TB patients.

You may also be interested in...

TB Drug Headed Toward Accelerated Approval: Another Wrinkle for Priority Review Vouchers

A positive advisory committee for Janssen’s bedaquiline means the second priority review voucher is probably on its way. And it would be the first for an accelerated approval.

India's Open Source Drug Discovery Initiative Compiles The TB Genome; Calls For Stronger Global Partnerships For Leads

MUMBAI - A decade after the mycobacterium tuberculosis genome sequence was deciphered, the Indian government's ambitious Open Source Drug Discovery initiative released what is claimed to be the first-ever comprehensive compilation of the mapped TB genome. The collated data will be made available through an open public portal for further analysis, leads and research collaborations

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts